Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial. (17th November 2017)

• Record Type: Journal Article
• Authors: Teyssier, Anne-Charlotte; Lapillonne, Hélène; Pasquet, Marlene; Ballerini, Paola; Baruchel, André; Ducassou, Stephane; Fenneteau, Odile; Petit, Arnaud; Cuccuini, Wendy; Ragu, Christine; Preudhomme, Claude; Mercher, Thomas; Sirvent, Nicolas; Leverger, Guy
• Is Part Of: Pediatric hematology and oncology. Volume 34:Number 8(2017)
• Page Start: 425
• Page End: 427
• Publication Date: 2017-11-17
• Subjects: AMKL -- ELAM02 -- pediatric acute megakaryoblastic leukemia; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Hematologic Diseases -- Child; Hematologic Diseases -- Infant; Neoplasms -- Child; 618.9215
• DOI: 10.1080/08880018.2017.1414905
• Languages: English
• ISSNs: 0888-0018

Abstract

ABSTRACT: We report the outcome of 27 children with de novo acute megakaryoblastic leukemia (AMKL) (excluding Down syndrome) enrolled in the French multicenter prospective study ELAM02 (2005-2011). There was no difference in gender, initial leukocyte count, CNS involvement, and complete remission rate (88.9%), as compared to other acute myeloid leukemia (AML) subtypes. AMKL patients had a significantly poorer outcome (5-year overall survival 54% [CI 95% 33%–71%] than children with other AML subtypes (5-year overall survival 73% [CI 95% 68%–77%] p = 0.02). Gender, age, CNS leukemia, hyperleukocytosis, complete remission or cytogenetic subgroups were not significant prognostic factors of disease-free survival. AMKL (excluding Down syndrom) remains an AML subgroup with inferior outcome.